USA - engelsk - NLM (National Library of Medicine)

bryant ranch prepack - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae, haemophilus influenzae, staphylococci, and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. lower respiratory tract infections, including pneumonia, caused by streptococcus pneumoniae, haemophilus influenzae, and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. pharyngitis and tonsillitis, caused by streptococcus pyogenes note: penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclo

USA - engelsk - NLM (National Library of Medicine)

a-s medication solutions - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae, haemophilus influenzae, staphylococci, and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. lower respiratory tract infections, including pneumonia, caused by streptococcus pneumoniae, haemophilus influenzae, and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. pharyngitis and tonsillitis, caused by streptococcus pyogenes note: penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections, including pyelonephritis and cystitis, caused by escherichia coli, proteus mirabilis, klebsiella spp., and coagulase-negative staphylococci skin and skin structure infections caused by staphylococcus aureus and streptococcus pyogenes appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor. to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor capsule and other antibacterial drugs, cefaclor capsule should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cefaclor monohydrate, quantity: 393.4 mg (equivalent: cefaclor, qty 375 mg) - tablet, modified release - excipient ingredients: mannitol; hypromellose; hyprolose; methacrylic acid copolymer; stearic acid; magnesium stearate; propylene glycol; purified talc; colour - indications as 16 december 1997: keflor cd is indicated for the treatment of the following types of infections caused by susceptible organisms, in adults and children aged 12 years or older: acute bronchitis and acute exacerbations of chronic bronchitis; upper respiratory infections, including pharyngitis, tonsillitis and acute bacterial sinusitis: community-acquired pneumonia of mild to moderate severity (excluding atypical pneumonia); symptomatic lower urinary tract infections, including cystisis; skin and skin structure infections. note 1. penicillin in the usual drug of choice in the treatment and prevention of streptoccocal infections, including the prophylaxis of rheumatic fever. keflor cd is generally effective in the eradication of streptococci from the oropharynx; however, substantial data establishing the efficacy of keflor cd in the subsequent prevention of rheumatic fever are not available. 2. bacteriological studies to determine the causative organism and its susceptibility to cefaclor should be performed. therapy may be started while awaiting the results of these studies. once these results become available, antimicrobial therapy should be adjusted accordingly.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - cefaclor monohydrate, quantity: 393.36 mg (equivalent: cefaclor, qty 375 mg) - tablet, modified release - excipient ingredients: hypromellose; colloidal anhydrous silica; hyprolose; lactose monohydrate; purified talc; magnesium stearate; titanium dioxide; macrogol 400; indigo carmine aluminium lake; propylene glycol; purified water; isopropyl alcohol; iron oxide black - for the treatment of the following infections caused by susceptible organisms, in adults and children 12 years and older: lower respiratory infections, including community acquired pneumonia of mild to moderate severity (excluding atypical pneumonia), acute bronchitis and exacerbation of chronic bronchitis. upper respiratory infections, including pharyngitis, tonsillitis and acute bacterial sinusitis. symptomatic lower urinary tract infections, including cystitis. skin and skin structure infections.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - cefaclor monohydrate, quantity: 393.36 mg (equivalent: cefaclor, qty 375 mg) - tablet, modified release - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; purified talc; hyprolose; hypromellose; magnesium stearate; propylene glycol; purified water; isopropyl alcohol; iron oxide black; titanium dioxide; macrogol 400; indigo carmine aluminium lake - for the treatment of the following infections caused by susceptible organisms, in adults and children 12 years and older: lower respiratory infections, including community acquired pneumonia of mild to moderate severity (excluding atypical pneumonia), acute bronchitis and exacerbation of chronic bronchitis. upper respiratory infections, including pharyngitis, tonsillitis and acute bacterial sinusitis. symptomatic lower urinary tract infections, including cystitis. skin and skin structure infections.

Canada - engelsk - Health Canada

pharmascience inc - cefaclor - capsule - 250mg - cefaclor 250mg - second generation cephalosporins

Canada - engelsk - Health Canada

pharmascience inc - cefaclor - capsule - 500mg - cefaclor 500mg - second generation cephalosporins

Canada - engelsk - Health Canada

pharmascience inc - cefaclor - powder for solution - 25mg - cefaclor 25mg - second generation cephalosporins

Canada - engelsk - Health Canada

pharmascience inc - cefaclor - powder for solution - 50mg - cefaclor 50mg - second generation cephalosporins

Canada - engelsk - Health Canada

pharmascience inc - cefaclor - powder for solution - 75mg - cefaclor 75mg - second generation cephalosporins